WEDNESDAY 11th NOVEMBER 2015 COMMENCING 9.30 AM
AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting
5. Chairman’s report (verbal update)
6. Appraisal 1 – Full Submission
   Insulin glargine (Abasaglar®) for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above
7. Appraisal 2 - Full Submission
   Sucroferric oxyhydroxide (Velphoro®) for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Sucroferric oxyhydroxide (Velphoro®) should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease
8. Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG – Data to March 2015
10. Appraisal 3 - Full Submission
    Tedizolid phosphate (Sivextro®) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults
11. Appraisal 4 – Limited Submission
    Raltegravir (Isentress®) in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of 4 weeks
12. **Appraisal 5 – Limited Submission**  
Adalimumab (Humira®) for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have an inadequate response to or are inappropriate candidates for topical therapy and phototherapies

13. **Appraisal 6 – Limited Submission**  
Tinzaparin sodium (innohep®) for the extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours

14. **Feedback from AWPAG Meeting held 23rd September 2015**

15. **All Wales Policy for Medicines Administration, Recording, Review, Storage and Disposal**

16. **All Wales Guidance for Health Boards/Trusts in Respect of Medicines and Health Care Support Workers**

To protect commercial confidentiality, the next appraisal will be conducted in private.

17. **Appraisal 7 – Limited Submission (PAS)**  
Denosumab (Xgeva®) for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity

The meeting will now re-open to the public for the announcement of the committee’s decision

Date of next meeting:  
Wednesday 9th December 2015 in Abergavenny